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New anti-epileptic drugs differ from existing standard therapies not in their clinical efficacy, but in their side-effects profiles. 
To determine the relative economic value of these agents, one must compare drug costs, costs of resources employed in the 
management of adverse vents, and costs associated with therapeutic switching. In this economic analysis, carbamazepine 
(CBZ) and lamotrigine (LTG) are evaluated in monotherapy treatment of partial and/or general tonic-clonic seizures in the 
UK. Adverse vent and tolerability data are obtained from a published randomized controlled trial of CBZ vs. LTG. A Delphi 
panel of clinicians advised treatment patterns for adverse vents. Cost data are obtained from public sources. Results show 
that CBZ therapy costs about one-third of LTG therapy (£179 for CBZ vs. £522 for LTG) even after the costs associated 
with the management of adverse vents and therapeutic switching are considered. 
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INTRODUCTION 
The current environment of cost consciousness in 
health care has resulted in a need for economic eval- 
uations of pharmaceuticals in order to identify those 
which provide the most value for money in treating 
patients. Thus, for conditions in which several com- 
peting drugs exist, economic analysis comparing the 
costs and outcomes of treatment with those drugs are 
becoming the norm. 
In the area of epilepsy, the appearance of new 
anti-epileptic drugs (AEDs) has also stimulated eco- 
nomic analyses to compare the costs and outcomes 
of using either new or established AEDs. Where im- 
proved efficacy cannot be shown, economic evalua- 
tions must measure the 'resource implications of dif- 
fering adverse-event profiles to assess the justification 
for higher prices, 
To assist in the choice of the most appropriate AED 
for initial therapy, an economic evaluation has been 
conducted which compares carbamazepine (CBZ) and 
lamotrigine (LTG). The evaluation focused on pa- 
tients with newly diagnosed epilepsy who are being 
treated with either LTG or CBZ as monotherapy for 
the first year of treatment. Patients have either partial 
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of generalized tonic-clonic seizures or both. 
The objective of this study is to evaluate 
whether the different rates of adverse events 
and the impact of changing treatment after with- 
drawal from treatment offset the difference in 
drug costs between lamotrigine and carbamazepine. 
The approach used in this study is cost min- 
imization analysis (CMA). This is appropri- 
ate when comparing the costs associated with 
different treatments with similar efficacy rates. 
Brodie et al  I demonstrated that LTG and CBZ 
have similar efficacy, but the overall success rate in 
terms of improved tolerability was better for LTG 
than CBZ. The analysis presented is based on the 
trial data reported by Brodie et al  1 . Different adverse- 
event profiles may also have differential impact on 
quality of life (QOL) for the patient, however, no 
appropriate data on QOL are available. 
The perspective of the study is that of the UK 
National Health Service (NHS). The analysis consid- 
ers the direct medical costs of treatment to the NHS. 
The disease and the treatment of adverse events as- 
sociated with drug therapy may also incur patient 
out-of-pocket expenditures and indirect costs to soci- 
ety in the form of productivity losses due to absence 
from work. However, these costs are not included 
as they are difficult to quantify from the information 
available. 












Fig. 1: A graphical representation of the clinical decision analytic model 
METHODS AND DATA SOURCES 
The model 
A clinical-decision analytic model was developed (us- 
ing an Excel spreadsheet) to calculate the annual cost 
of treatment with each drug. The model takes into 
account he cost of drug therapy, the rate and cost of 
adverse events and changing therapy after treatment 
failure (withdrawal due to adverse vents). The model 
follows patients for 1 year: patients tart therapy on 
either CBZ or LTG. Patients may develop side effects 
and either the side effects resolve or the patient with- 
draws and is switched to an alternative drug therapy. 
A graphical representation of the model is shown in 
Fig. 1. 
Assumptions 
The following assumptions were made which are dis- 
cussed further in this section. 
This evaluation focuses on the resources used in 
the treatment of adverse vents and not those used 
in routine care. The health-care resources used in 
routine care were assumed to be the same for both 
drugs, as no differences in efficacy were shown. 
The adverse-event treatment patterns assumed 
that the adverse-event episodes are mutually ex- 
clusive. 
Stay on CBZ 
P = 0.73 
P = 0.27 
Switch to valproate 
A. Shakespeare & G. Simeon 
Drug cost 57 
AE cost 88 
Total 14_~5 
Drug cost 110 
Switching 72 
AE cost 88 
Total 270 
Stay on LTG 
P=0.85 
P=0.15 
Drug cost 485 
AE cost 80 
Total 56___~5 
Switch to CBZ 
Drug cost 11 I 
Switching 72 
AE cost 87 
Total 270 
(costs shown in £). 
Patients who withdraw while taking CBZ are 
switched to sodium valproate and those taking 
LTG to CBZ. Anti-epileptic drug efficacy was 
assumed to remain similar if a patient switched 
drug therapy. It was also assumed that patients 
switched to sodium valproate would have a simi- 
lar rate of adverse vents as for CBZ. 
Data sources 
The model was based on three sources of data: clin- 
ical trial data, expert clinical opinion, and published 
literature. Clinical trial data were used for rates of ad- 
verse events and withdrawal. Expert opinion was used 
to identify treatment patterns for the adverse events 
reported in the trial, in the absence of primary data 
sources. Published literature was used to obtain cost 
data and ranges for sensitivity analysis. 
Patient outcomes 
The rates of adverse events and withdrawal rates re- 
ported by Brodie et al. were used as the basis for 
this economic evaluation. To our knowledge only one 
double-blind randomized clinical trial I has been pub- 
lished in which CBZ and LTG (monotherapy) are 
compared in patients with newly diagnosed epilepsy 
in the UK. This trial was a double-blind, random- 
ized parallel group comparison, following 260 pa- 
tients (aged 13 years and over) for 48 weeks. After 
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Table 1: Adverse event rates for lamotrigine and 
carbamazepine 
Percentage of patients 
Lamotrigine (%) Carbamazepine (%)
(n= 131) (n= 129) 
Headache 30 25 
Asthenia 21 29 
Rash 19 29 
Nausea 18 12 
Dizziness 12 17 
Sleepiness a 12 22 
Flu-like symptoms 11 8 
Pharyngitis 9 7 
Vomiting 9 7 
Rhinitis 8 5 
Amnesia 6 3 
Infection 6 5 
Back pain 5 2 
Depression 5 9 
Ataxia 3 9 
Events were reported by at least 5% of patients in a group. 
a p < 0.05. 
randomization there was a period of dose escalation 
in which patients received increasing doses of 50 mg 
LTG and 200 mg of CBZ so that at 4 weeks all pa- 
tients were taking either LTG 150 mg/day or CBZ 
600 mg/day. This dose was maintained throughout 
the trial with adjustment for seizures as necessary. 
Eff icacy.  No significant differences in the proportion 
of patients maintained seizure free on either drug ther- 
apy were reported in the trial. 
Adverse -event  rates .  The adverse-event rates for 
LTG and CBZ used are documented in Table 1. The 
rate of sleepiness was the only adverse event which 
was significantly different between the two groups of 
patients. 
Information on the severity of adverse events and 
their relationship to trial medication was not reported. 
Some of the adverse events such as rhinitis are un- 
likely to be related to drug therapy but are only re- 
ported because of the trial protocol. 
Switching drugs after withdrawal. Withdrawal rates 
due to adverse vents reported by Brodie et  a l  I were 
used as a proxy for switching therapy. The rate of 
withdrawal due to adverse vents was 15% in patients 
taking LTG and 27% in patients taking CBZ. 
If a patient withdrew from drug therapy, it was as- 
sumed that the patient would switch to an alternative 
regimen; patients taking CBZ would be switched to 
sodium valproate (1000 mg/day) and patients taking 
LTG to CBZ (600 mg/day). It was assumed that pa- 
tients would remain on this regimen for the rest of 
the year, with the adverse-event rates and costs of 
the AED to which the change was made. The choice 
of the alternative drug regimen was based on expert 
opinion of practice in the UK. In the absence of 
121 
suitable trial data, the efficacy rate and rate of ad- 
verse events in patients witched to sodium valproate 
were assumed to be similar to CBZ. Sensitivity anal- 
ysis was conducted to examine the implications of 
switching therapy and the choice of the alternative 
drug regimen. 
The mean time of withdrawal due to adverse vents 
after starting a drug therapy was not reported by 
Brodie et  a l  I . A mean time to withdrawal of 6 weeks 
was used based on clinical opinion. Sensitivity analy- 
sis was conducted to examine the impact of this pa- 
rameter on the results. 
Resource utilization 
Costs of adverse events were developed in consulta- 
tion with specialists in epilepsy care as no detailed in- 
formation on the management of adverse vents was 
available from the literature or databases. Previous 
economic analyses have either not examined the treat- 
ment of adverse events in detail 2 or this aspect has 
not been fully reported. Navarro and Ashraf 3 calcu- 
lated different adverse-event treatment costs based on 
a physician panel; however, the additional resources 
utilized were not fully documented. 
The expert panel consisted of four specialists in 
epilepsy care. A questionnaire was designed to col- 
lect information on treatment patterns and was ad- 
ministered by mail with telephone follow-up, where 
necessary. Typical treatment patterns for each adverse 
event were derived based on the mean value of the 
physician responses. 
Hospital-based epilepsy specialists were the focus 
of this exercise and were used to estimate resource 
use in both the hospital and general-practice s tting. 
Although general practitioners (GPs) provide consid- 
erable care for patients with epilepsy it was decided 
not to consult GPs in this case for the following rea- 
sons: the care of the newly diagnosed patient is usu- 
ally the responsibility of the neurologist who would 
be responsible for making therapy changes, although, 
once the patient is stabilized on maintenance therapy 
he will be referred back to his GP. The average GP 
is unlikely to have substantial experience of treating 
drug-related adverse vents, as he is not likely to have 
more than 20 patients with epilepsy. However, there 
may be regional variations in treatment practice, in 
some areas waiting time for a neurology consultation 
is so long that a GP may initiate treatment. 
The questionnaire focused on changes in drug ther- 
apy and health-care resources utilized specifically for 
the adverse vents. For each adverse vent questions 
were asked to establish how the typical patient is 
managed; if management of the adverse event alters 
standard AED therapy; if management of the event 
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Table 2: Example treatment patterns 
A. Shakespeare & G. Simeon 
Resource type Headache Rash Asthenia 
AED therapy changes Dose reduction Dose reduction 
CBZ (43%) CBZ (28%) 
LTG (44%) LTG (28%) 
Switch drug therapy CBZ (3%) CBZ (94%) 
LTG (4%) LTG (94%) 
Medical Neurologist: Neurologist: Neurologist: 
consultations Office visit (16%) Office visit (28%) Office visit (21%) 
Telephone (35%) Telephone (60%) Telephone (16%) 
Two GP attendances (60%) 
Additional Paracetamol (30%) 
drugs 
Other 
Two GP attendances (78%) 
Two dermatologist at endances (1%) 
Prednisolone, 14days (3%) 
Antihistamine, 14 days (5%) 
Hospital admission, 5 days (4%) 
One GP attendance (44%) 
Tests AED levels (25%) FBC, U&Es, LTF (CBZ, 40%; LTG, 53%) 
Percentages in parentheses r fer to the proportion ofpatients utilizinga particular resource. 
CBZ = carbamazepine, FBC = full blood count, LTG = lamotrigine, U&E = urea and electrolytes+ LFT = liver function test. 
Table 3: Cost per resource unit 
Resource Cost per unit Source 
(£ 1994/95) 
Outpatient eurologist consultation 72.01 CIPFA, 19954 
General practitioner consultation (surgery visit) 16.00 PSSRU, 19957 
Dermatologist 41.63 CIPFA, 19954 
Psychiatrist 82.02 CIPFA, 19954 
Neurology inpatient day 217.30 CIPFA, 19954 
Psychiatry inpatient day 109.29 
Tests 
Full blood count 5 
Urea and electrolytes 6 
Liver function test 6 
AED levels 11.39 
EEG 77.45 
Brain imaging I00 
Additional drug therapy 
Sodium valproate (Epilim, 1000 mg/day) 
Prednisoline (20 mg/day) 
Chlorphrenamine (30mg/day) 
Metoclopramide (30 mg/day) 
Fluoxetine (20 mg/day) 
Paracetamol (4 g/day) 
JS Pathology Services, 19948 
JS Pathology Services, 19948 
JS Pathology Services, 19948 
Swingler eta/, 19949 
Swingler et al, 19949 
NHS health care trust, 1995 
0.32 per day BNF, September 19955 
0.03 per day BNF, September 19955 
0.06 per day BNF, September 19955 
0.23 per day BNF, September 19955 
0.69 per day BNF, September 19955 
0.04 per day BNF, September 19955 
differs according to the AED; and what health-care 
resources are used to manage the adverse event, in 
addition to those used in routine treatment. Treat- 
ment patterns which reflect he typical pattern of care 
rather than 'ideal' practice were requested. 
The treatment patterns are based on the assump- 
tion that the patients uffers only one adverse vent 
at a time, as no data were available on the rates of 
concurrent events. This may result in some double 
counting of resource utilization, for example, a pa- 
tient suffering nausea nd dizziness at the same time 
would probably have both adverse events managed 
in the same consultation. 
Example of the treatment patterns for each adverse 
event are shown in Table 2. The frequency of use, 
proportion of patients and reduction in drug doses 
are mean values of the estimates provided by the 
physicians. 
Unit cost  
The unit prices used to convert he treatment patterns 
into costs for each adverse vent were based on na- 
tional databases and published studies. The principal 
sources of data were the CIPFA database of UK NHS 
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Table 4: Cost per adverse-event episode 
Adverse vent Cost per episode (£ 1994/95) 
Carbamazepine Lamotrigine 
Headache 46.40 46.25 
Asthenia 28.15 28.05 
Rash 120.10 122.20 
Nausea 28.10 27.80 
Dizziness 54.70 54.30 
Sleepiness 41.00 40.60 
Flu-like symptoms 19.00 19.00 
Pharyngitis 22.00 22.00 
Vomiting 45.70 45.40 
Rhinitis 5.70 5.70 
Amnesia 68.90 68.90 
Infection 0 0 
Backpain 0 0 
Depression 136.30 136.30 
Ataxia 36.00 35.40 
costs 4, the British National Formulary 5, commercial 
laboratories, and research studies. Costs were updated 
to 1994/95 where necessary using the Hospital and 
Communi~ Health Services Inflation Index (HCHS) 6. 
Costs were not discounted as the time frame of the 
analysis is only 1 year. 
Drug costs were calculated using the prices for the 
brand-name products quoted in the British National 
Formulary 5. These are basic net prices to the NHS 
and exclude overhead allowances. The annual cost of 
CBZ (Tegretol) 600 mg/day was £57.45 and LMG 
(Lamictal) 150 mg/day was £484.54. 
The individual costs and sources are shown in 
Table 3. 
Adverse-event costs. The costs for each adverse- 
event episode are shown in Table 4. They were cal- 
culated by applying the unit costs (Table 3) to the 
resources used (Table 2). 
Withdrawal and switching drugs. The cost  of with- 
drawing and switching drug therapy was £72.014 , 
which was the cost of neurologist consultation. 
Sensitivity analysis. Sensitivity analyses were con- 
ducted on key parameters: drug dose, proportion of 
patient switch therapy, the time of therapy switch and 
the choice of drug switched to. 
RESULTS 
Base case 
The annual average costs per patient (excluding the 
cost of routine care) was calculated for a patient 
treated successfully (who did not switch therapy) with 
CBZ or LTG and for those who switched drug ther- 
apy. These average costs for the base case are shown 
in Table 5. 
123 
Table 5: Average cost per successful patient and for 
switching (1 year) 
Carbamazepine Lamotrigine 
(£) (£) 
Successful treatment 145.63 564.44 
Switch treatment 269.86 269.99 




Drug costs 71.66 (40%) 430.34 (82%) 
Adverse vent costs 88.15 (49%) 80.95 (16%) 
Switching (consultation) 19.54 (11%) 10.44 (2%) 
Total cost 179.34 521.74 
The average cost for a successfully treated patient 
includes the cost of drug therapy and treating adverse 
events. For those patients who switch therapy, the to- 
tal annual cost includes drug costs (6-weeks treated 
with CBZ switched to sodium valproate for the rest 
of the year or LTG switched to CBZ), adverse-event 
costs (incurred before and after switching) and the 
cost of a neurology consultation for the drug switch. 
The average annual cost per patient aking CBZ or 
LTG was calculated using a weighted average of the 
cost of a successful treatment and switching based on 
the proportion of patients in each category. The pro- 
portion of patients who switch drug therapy is 27% 
of patienis taking carbamazepine and 15% of patients 
taking lamotrigine. The average annual cost for each 
drug and the distribution of costs for the base case 
are shown in Table 6. 
The average costs for a year of treatment was 
£179.34 for patients taking CBZ and £521.74 for pa- 
tients taking LTG. Treatment with CBZ cost £342.40 
less than with LTG. 
Sensitivity analysis 
Sensitivity analyses were conducted on the following 
parameters and the results are documented in Table 7. 
UK drug doses. The results were calculated using the 
cost of drug therapy based on the mean daily doses 
of CBZ (800 mg) and LTG (250 mg) suggested by 
UK physicians. The drug costs for 1 year of treat- 
ment at these doses is £76.65 for CBZ and £807.56 
for LTG. 
Proportion of patients switching therapy. The propor- 
tion of patients who switched therapy was adjusted 
to 10% for CBZ patients and 4.5% for LTG to reflect 
the rates reported by Yuen I°. 
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Table 7: Sensitivity analysis 
A. Shakespeare & G. Simeon 
Sensitivity analysis Carbamazepine Lamotrigine Difference incost 
(£) (£) (£) 
Base case 179.34 521.74 342.40 
UK physician-recommended m an drug doses 193.95 806.20 612.25 
Switching drug therapy a 158.06 551.19 393.14 
Time of switch 
1 month 180.01 519.20 339.19 
2 months 178.66 524.27 345.60 
3 months 177.31 529.33 352.02 
4 months 175.97 543.39 358.43 
5 months 174.62 539.45 364.84 
6 months 173.27 544.52 371.35 
Carbamazepine patients witched to lamotrigine 264.60 521.74 257.14 
a Proportion of patients witching drugs: CBZ 10%, LTG 4.5%. 
Switching drug therapy time. The mean time at which 
drug therapy was switched was varied from 1 to 
6 months. 
Drug switched to. A sensitivity analysis was con- 
ducted in which patients taking CBZ who withdrew 
were switched to LTG instead of sodium valproate. 
This increases the average annual cost of CBZ ther- 
apy to £264.60 and decreases the difference in cost 
between treatment with LTG and CBZ to £257.14. 
DISCUSSION 
Drug costs and the cost of withdrawal are the key 
issues in this evaluation. The cost of treating adverse 
events was similar for both drugs. Drug costs account 
for a substantial proportion of the average cost per 
patient for both drugs (CBZ 40%, LTG 82%). The 
cost of switching primarily reflects the cost of the 
drug switched to. Therefore, switching drug therapy 
is cost saving for patients taking LTG as patients are 
switched to CBZ, a significantly cheaper drug. The 
annual cost for a patient who switches drug ther- 
apy to CBZ from LTG is £270 compared with £562 
for a year of successful treatment. Sensitivity analy- 
sis demonstrated that significant cost savings (£257) 
remain even when patients taking CBZ initially are 
switch to LTG instead of valproate. 
When considering the results of this economic eval- 
uation a number of limitations must be recognized. 
The economic evaluation is based on one clinical 
trial, therefore, consideration must be given to the 
generalizability of this to clinical practice in the UK. 
Clinical trials often do not reflect real clinical prac- 
tice, for example, due to the nature of trial inclusion 
and exclusion criteria and the reporting of adverse 
events. Adverse events were assumed to be mutu- 
ally exclusive and treatment patterns were estimated 
based on this assumption. Health-care resource uti- 
lization was also assumed to be equal for both drugs 
except for adverse events. The adverse-event treat- 
ment patterns were based on expert opinion and these 
require validation, preferably using either retrospec- 
tive or prospective patient data collection. 
The rates of adverse vent and withdrawal reported 
by Brodie et al I have been the subject of much dis- 
cussion, which was used to guide the sensitivity anal- 
yses conducted. The adverse event rates for carba- 
mazepine were higher than those reported in other 
studies, for example, the Veterans Administration co- 
operative studies 3. These studies did not include com- 
parison of LTG and CBZ drug therapy so it is not pos- 
sible to apply these data to this analysis. However, the 
rate of adverse vents in patients taking CBZ would 
have to be over seven times greater than with LTG to 
offset cost differences. 
The CBZ dose escalation schedule used in the 
Brodie trial has been criticized for not representing 
clinical practice 1I. 12. It was suggested that the dose- 
escalation schedule used in the trial is faster than the 
usual practice of many neurologists. This factor may 
account for the differences in tolerability between 
LTG and CBZ. Studies with slower escalation sched- 
ules have indicated lower rates of withdrawal due to 
adverse vents in patients taking CBZ and LTG 1°' 13 
An open trial of CBZ and LTG monotherapy in pa- 
tients with newly diagnosed and recurrent epilepsy 
reported withdrawal rates of 10.3% in patients tak- 
ing CBZ and 4.3% and 4.5% in patients taking LTG 
(100 mg and 200 mg doses respectively). This rate 
of withdrawal in CBZ patients is similar to the rate 
observed in a pragmatic randomized trial (11% at 30 
months) 13. 
The formulation of CBZ used in the Brodie trial 
may also help to explain the adverse-event rates re- 
ported. The trial used the immediate-release formu- 
lation rather than the modified-release formulation of 
CBZ (Tegretol Retard). Use of the controlled-release 
formulation significantly reduces the rate of adverse 
events 5,14 and withdrawal in the CBZ group. 
Quality of life is not considered in this cost- 
minimization study and its estimation is vital where 
alternative therapies are associated with both bene- 
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ficial and harmful effects. In this case, although ef- 
ficacy in patients tolerating treatment is considered 
to be similar for the two therapies, adverse events 
and the process of changing therapy could have an 
adverse impact on QOL. If this were the case then 
the average QOL of patients could potentially be 
lower when treated with the drug causing most ad- 
verse events, but data are not available to test this 
hypothesis. Both the number, type and severity of 
adverse vents will have an impact on health-related 
QOL. The appropriate analytic framework in which 
to test the importance of any QOL change would be 
a cost-utility study. However, information on QOL 
in patients with epilepsy is limited 15 and appropriate 
QOL data are not available to evaluate the impact of 
different AED therapies. 
CONCLUSIONS 
The results of this evaluation indicate that under base- 
case assumptions treatment with CBZ is cost saving 
when compared with LTG as monotherapy in patients 
with newly diagnosed epilepsy. The average cost per 
patient reated with CBZ (£179.34) is 34% of the av- 
erage cost of treatment with LTG (£521.74). The costs 
of adverse vents and switching therapy do not off- 
set the additional cost of LTG therapy. In sensitivity 
analysis the results appear obust under changing cir- 
cumstances. The results of this study are supported by 
the US analysis conducted by Navarro and Ashraf 3. 
Based on their calculation of adverse-events costs, 
similar cost savings with CBZ treatment would be 
expected. Health-care providers and purchasers need 
to consider whether the advantages in tolerability re- 
ported by Brodie et a/l justify an addition £342 per 
patient annual cost for treatment with LTG. 
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